Philina Lee's most recent trade in Blueprint Medicines Corp was a trade of 3,733 Common Stock done at an average price of $88.8 . Disclosure was reported to the exchange on March 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 88.80 per share. | 05 Mar 2025 | 3,733 | 41,996 (0%) | 0% | 88.8 | 331,490 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 11,000 | 45,729 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 93.19 per share. | 05 Aug 2024 | 41,913 | 34,729 (0%) | 0% | 93.2 | 3,905,872 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 12,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 86.60 per share. | 05 Aug 2024 | 12,350 | 76,642 (0%) | 0% | 86.6 | 1,069,510 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 10,572 | 6,928 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.31 per share. | 05 Aug 2024 | 10,572 | 64,292 (0%) | 0% | 61.3 | 648,169 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 8,450 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 54.13 per share. | 05 Aug 2024 | 8,450 | 53,720 (0%) | 0% | 54.1 | 457,399 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 5,011 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 81.44 per share. | 05 Aug 2024 | 5,011 | 40,939 (0%) | 0% | 81.4 | 408,096 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 4,331 | 20,669 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 43.15 per share. | 05 Aug 2024 | 4,331 | 45,270 (0%) | 0% | 43.2 | 186,883 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 1,042 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 51.06 per share. | 05 Aug 2024 | 1,042 | 35,928 (0%) | 0% | 51.1 | 53,205 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.05 per share. | 05 Aug 2024 | 157 | 34,886 (0%) | 0% | 36.1 | 5,660 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2024 | 157 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 90.55 per share. | 13 Mar 2024 | 6,223 | 36,529 (0%) | 0% | 90.6 | 563,493 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 89.88 per share. | 13 Mar 2024 | 1,800 | 34,729 (0%) | 0% | 89.9 | 161,784 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.01 per share. | 13 Mar 2024 | 1,224 | 42,752 (0%) | 0% | 15.0 | 18,372 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.80 per share. | 13 Mar 2024 | 523 | 41,528 (0%) | 0% | 8.8 | 4,602 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 90.69 per share. | 07 Mar 2024 | 2,934 | 41,005 (0%) | 0% | 90.7 | 266,084 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 12,500 | 43,939 (0%) | 0% | 0 | Common Stock | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.87 per share. | 13 Dec 2023 | 261 | 31,439 (0%) | 0% | 1.9 | 488 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Dec 2023 | 261 | 0 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 45.72 per share. | 06 Mar 2023 | 1,622 | 31,232 (0%) | 0% | 45.7 | 74,158 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 44.41 per share. | 06 Mar 2023 | 54 | 31,178 (0%) | 0% | 44.4 | 2,398 | Common Stock |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Blueprint Medicines Corp | Philina Lee | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 12,500 | 32,854 (0%) | 0% | 0 | Common Stock | |
| Fusion Pharmaceuticals Inc | Philina Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Philina Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2021 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Fusion Pharmaceuticals Inc | Philina Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) |